Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. This activity is supported by independent medical ...
Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...
Please provide your email address to receive an email when new articles are posted on . This activity is supported by independent medical education grants from 4D Molecular Therapeutics; AbbVie Inc.; ...
Dec 31 (Reuters) - Outlook Therapeutics (OTLK.O), opens new tab said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, dealing another blow in the ...
Even as OpenAI works to harden its Atlas AI browser against cyberattacks, the company admits that prompt injections, a type of attack that manipulates AI agents to follow malicious instructions often ...
An announcement from Alvotech ( (ALVO)) is now available. On December 19, 2025, Alvotech reported that it and its U.S. commercial partner Teva Pharmaceuticals have reached a settlement and license ...
Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) have reached a settlement and license agreement with Regeneron Pharmaceuticals (REGN) concerning the launch of AVT06, Alvotech’s proposed biosimilar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback